Akèy › Myelofibroz › Alabama
Etid klinik pou Myelofibroz nan Alabama
7 etid pou Myelofibroz ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- University of Alabama, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04176198Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- University of Alabama At Birmingham, Birmingham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1
4 Weeks – 75 Years · Tout sèks · Mizajou Apr 13, 2026 · NCT06047886A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- University of Alabama Birmingham, Birmingham
Ap rekriteFaz 2
Laj 18 a 66 · Tout sèks · Mizajou Mar 17, 2026 · NCT06859424SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- UAB Hospital, Birmingham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2025 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- University of Alabama at Birmingham, Birmingham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Feb 21, 2023 · NCT05280509Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.